Le medicament du mois. Combinaison fixe perindopril-amlodipine (Coveram) dans le traitement de l'hypertension arterielle et de l'insuffisance coronaire.

in Revue Médicale de Liège (2009), 64(4), 223-7

Coveram is a new fixed combination of an angiotensin converting enzyme inhibitor, perindopril, and a calcium antagonist, amlodipine. This new medication is indicated for the treatment of arterial ... [more ▼]

Coveram is a new fixed combination of an angiotensin converting enzyme inhibitor, perindopril, and a calcium antagonist, amlodipine. This new medication is indicated for the treatment of arterial hypertension and/or stable coronary heart disease. Such fixed combination of two molecules that have been extensively evaluated according to evidence-based medicine offers the advantage of an excellent efficacy, associated with a good tolerance profile, and favours patient's compliance. The marketing of different formulations of Coveram combining various dosages allows easy adjustment and titration of each of the components according to the individual patient's characteristics. [less ▲]

Indexing glomerular filtration for body surface area is misleading in obese subjects: reductio ad absurdum.

Poster (2009)

Les anticorps monoclonaux en transplantation rénale

in Revue Médicale de Liège (2009), 64(5-6), 287-292

Renal transplantation is the best treatment for end-stage renal disease, but requires efficient immunosuppressive therapy. The latter has evolved over recent years with the development of more powerful ... [more ▼]

Renal transplantation is the best treatment for end-stage renal disease, but requires efficient immunosuppressive therapy. The latter has evolved over recent years with the development of more powerful drugs and of monoclonal antibodies with very specific target. The first monoclonal antibodies, acting against the interleukin 2 receptor, named basiliximab and daclizumab, have showed an excellent tolerance profile and efficacy to reduce acute graft rejection. However, in spite of these properties, the development of delayed graft function or the graft and patient survivals at 1 year were not modified by the use of such specific treatment. One potential advantage could yet be a decreasing need for corticosteroids and sometimes calcineurin inhibitors which could provide some long term benefits for the renal graft, but also the patient. Alemtuzumab, another monoclonal antibody, aimed at the membrane glycoprotein CD52, can also decrease the incidence of acute rejection and the depth of the required immunosuppressive therapy. Other antibodies are still in development with some interesting preliminary results which however demand confirmation in larger studies. [less ▲]

Comparison of BNP and NT-proBNP performances for assessing heart failure in a population of patients with high incidence of with renal insufficiency

in Annales de Biologie Clinique (2009), 67(1),

Analysis of factors affecting the ankle-brachial index (ABI) in hemodialysis patients (HD), a 4 year longitudinal study

Poster (2008, December 13)

Insuffisance rénale chronique : "Epidemiology of CVRF"

Conference (2008, December 05)

Hypertension artérielle et sport

Conference (2008, November 18)

Angioplastie-stenting de l'artère rénale : pour quel patient, sur quelles bases, avec quels résultats?

Conference (2008, November 15)

Screening for Proteinuria and Chronic Kidney Disease Risk Factors in Kinshasa:A World Kidney Day 2007 Study

in Nephron. Clinical Practice (2008), 110

Abstract Background: Although screening programs for chronic kidney disease (CKD) may be of great value, these programs are not yet implemented in the Democratic Republic of Congo. This study focused on ... [more ▼]

Abstract Background: Although screening programs for chronic kidney disease (CKD) may be of great value, these programs are not yet implemented in the Democratic Republic of Congo. This study focused on proteinuria and examined its prevalence in terms of the number needed to screen for the different risk factors of CKD. Such knowledge would guide the utility of population screening to prevent end-stage renal disease. Methods: A cross-sectional survey was conducted in Kinshasa on the Second World Kidney Day. A sample of 3,018 subjects was interviewed and the following measurements were performed: blood pressure, body mass index, glycemia and urine protein. Logistic regression analysis was used to identify determinants of proteinuria. Results: The prevalence of proteinuria was 17.1% (95% CI 15.8–18.6). Other CKD risk factors identified were: hypertension, diabetes mellitus, obesity and metabolic syndrome. To identify 1 case of proteinuria, one would need to screen 4 persons with dia-betes, 5 persons with hypertension, 4 subjects having metabolic syndrome, 5 persons aged 6 72 years and 9 persons without any of the conditions mentioned above. Age, overweight and diabetes were the strongest factors associated with proteinuria. Conclusions: This study indicates that proteinuria and traditional risk factors for CKD are very prevalent in Kinshasa. Realistic policies to stem these conditions should be a public health priority. [less ▲]

Le don d'organes

Conference given outside the academic context (2008)

Conférence grand public dans le cadre du programme de dépistage de l'insuffisance rénale de la Province de Liège